A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

By H. Braat, P. Rottiers, D. Hommes, N. Huyghebaert, E. Remaut, J. Remon, S. V. van Deventer, S. Neirynck, M. Peppelenbosch, L. Steidler. Clinical Gastroenterology and Hepatology, 2006

786 citations recorded by the source corpus.

Subfields: Biotechnology, Food Science, Genetics

View Paper: https://www.semanticscholar.org/paper/aee8ff477735622f6c7e2b6c6fbd4a543ed0a444

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. F. Powrie
2. M. Pohin
3. DM Mosser
4. X. Zhang
5. Zhesheng Chen
6. M. Friedrich

Citations in the corpus

• Macrophage activation by endogenous danger signals (2008, background): “A clinical Phase I trial with transgenic Lactococcus lactis to produce human IL-10 has shown efficacy in 10 patients with Crohn’s disease [135], suggesting that induction of IL-10 in the local intestinal mucosa may be a better therapeutic option.”
• Microbiota in health and diseases (2022, background): “Moreover, an engineered Lactococcus lactis strain which secretes the anti-inflammatory cytokine IL-10 showed a clinical benefit in CD.(389) Insulin production in epithelial cells can be induced by the gut hormone GLP.”
• Probiotics and prebiotics - Progress and challenges (2008, background): “The creation of a Lactococcus lactis LL-Thy12 strain expressing human interleukin-10 (IL-10) is a development of potential clinical significance (Braat et al., 2006).”
• Interleukin-10: new perspectives on an old cytokine (2008, background): “Early studies in mice resulted in a 50% decrease in experimental colitis (82), and in Phase I human clinical trials the genetically engineered bacteria were well tolerated in a small group of patients (83).”
• Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, background): “safe (Braat et al., 2006) and ameliorates DSS-induced and IL-10 deficiency colitis (Steidler”
• Probiotics and the gut microbiota in intestinal health and disease (2010, background): “Mucosal Immunology Laboratory, Gastroenterology Division, Massachusetts General Hospital for Children, Harvard Medical School, 114 16th Street (114-3503), Charlestown, MA 02129-4404, USA (W.”